ISL
BMY.RT

Ingalls & Snyder LLC’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Ingalls & Snyder LLC’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-14,250
Closed -$10K – 460
2020
Q4 		$10K Sell
14,250
-88,926
-86% -$189K ﹤0.01% 424
2020
Q3 		$232K Buy
103,176
+125
+0.1% +$357 0.02% 331
2020
Q2 		$369K Sell
103,051
-235
-0.2% -$848 0.02% 296
2020
Q1 		$392K Sell
103,286
-1,563
-1% -$5.15K 0.03% 287
2019
Q4 		$316K Buy
+104,849
New +$273K 0.02% 317

Other funds holding BMY.RT

JCI
Jet Capital Investors New York $51M AUM 48.01% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
BC
Brookfield Corp Toronto, Ontario, Canada $74.2B AUM 0.68% 1-Year Est. Return
TNB
Thomasville National Bank Thomasville, Georgia $1.61B AUM 22.15% 1-Year Est. Return
WAM
Westport Asset Management Southport, Connecticut $226M AUM 16.76% 1-Year Est. Return
IAIM
International Assets Investment Management Orlando, Florida $1.44B AUM 21.92% 1-Year Est. Return

Ingalls & Snyder LLC's BMY.RT Position: Q1 2021 in Review

Ingalls & Snyder LLC sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q1 2021, closing a stake of 14,250 shares — an estimated $10K sold.

Ingalls & Snyder LLC first reported a position in BMY.RT in Q4 2019 and held it in 5 quarters. The position peaked at $392K in Q1 2020. 12 funds tracked by Wall St. Rank hold BMY.RT as of Q1 2021.

  • Ingalls & Snyder LLC reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q1 2021 after selling out during the quarter.
  • Ingalls & Snyder LLC sold 14,250 Bristol-Myers Squibb Company Contingent Value Rights shares in Q1 2021, an estimated $10K.
  • Ingalls & Snyder LLC first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2019 and held it in 5 quarters.
  • Ingalls & Snyder LLC's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $392K in Q1 2020.
  • 12 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q1 2021.

Based on Ingalls & Snyder LLC's 13F filing for Q1 2021, filed 21 Apr 2021.